Replies to post #123035 on NorthWest Biotherapeutics Inc (NWBO)

[TiltMyBrain]

Lol!!!

[padres3371]

closer to 3%; dcvax might give you 20+%; 7x greater!!!

[biosectinvestor]

You left this out, from your link:

"However, survival rates vary widely and depends on several factors, including the type of brain or spinal cord tumor. Talk with your doctor about what to expect with your diagnosis."

There are many low-grade tumors, meaning slow growing tumors, that can be treated with solid results. Apparently, you're new to this?

From the clinical trial Eligibility requirements:

https://clinicaltrials.gov/ct2/show/NCT00045968

Patients with newly diagnosed, unilateral GBM (Grade IV)

In this context, there is more specific information than you've provided. Though I suspect you likely already, in fact, know this...

http://braintumor.org/brain-tumor-information/understanding-brain-tumors/tumor-types/

World Health Organization (WHO) Updates Official Classification of Tumors of the Central Nervous System

On May 9, 2016, the World Health Organization (WHO) published an official reclassification of Tumor Types of the Central Nervous System, which has moved the greater neuro-oncology field toward a more precise and accurate system of brain tumor classification. Based on information from expert neuropathologists and neuro-oncologists, the result of the updated WHO classifications, which integrate molecular information with histology, is that doctors will be better able to more accurately diagnose, make prognoses, plan treatment, and predict therapeutic response for patients. A more precise diagnosis and treatment plan is a win for patients.

Since the advent of new technology and capabilities for genomic sequencing, and in particular the seminal Cancer Genome Atlas project funded by the National Institutes of Health, recent molecular studies on brain tumors have begun to reveal the vast diversity of genetic and epigenetic alterations that exist between brain tumors. This biological heterogeneity often means tumors that may, at first blush, appear to be the same, may actually require a different approach to treatment – as well as the converse (i.e. tumors that may look different under the microscope may have common molecular alterations). Further studies have also shown that molecular signatures in tumor cells can define different groups of brain tumor types with distinctive characteristics, and that analyzing a tumor for mutations or deletions in certain genes or regions of chromosomes, can provide a deeper level of understanding of each tumor’s make-up.

Thus, it was critical that molecular data be integrated into traditional histopathology approaches to reclassify brain tumor types more effectively.

New integrated classifications will also improve future research and the development of new treatments by ensuring that patients participating in clinical trials are comparable within and across trials, and patients in clinical trials are correctly stratified based on their molecular signatures with targeted therapies most likely to benefit them. Additionally, the updated classifications will help provide more accurate analysis and understanding of experimental studies in the lab, as well as better interpretation of population-based disease trends that may help identify causes and risk factors. In short, this move away from traditional histopathology alone, to integrated classification with molecular characteristics, moves the brain tumor field further into the era of medicines that are highly targeted for a particular brain tumor patient.

You can access the reclassification document HERE.

Information below will be updated soon.

There are more than 120 types of brain and central nervous system (CNS) tumors. Today, most medical institutions use the World Health Organization (WHO) classification system to identify brain tumors. The WHO classifies brain tumors by cell origin and how the cells behave, from the least aggressive (benign) to the most aggressive (malignant). Some tumor types are assigned a grade, ranging from Grade I (least malignant) to Grade IV (most malignant), which signifies the rate of growth. There are variations in grading systems, depending on the tumor type. The classification and grade of an individual tumor help predict its likely behavior. This section describes the most frequently diagnosed types.



Grade IV – Glioblastoma (GBM)

Glioblastoma multiforme (GBM) is the most common and deadliest of malignant primary brain tumors in adults and is one of a group of tumors referred to as gliomas.

Classified as a Grade IV (most serious) astrocytoma, GBM develops from the lineage of star-shaped glial cells, called astrocytes, that support nerve cells.

GBM develops primarily in the cerebral hemispheres but can develop in other parts of the brain, brainstem, or spinal cord.

Because of its lethalness, GBM was selected as the first brain tumor to be sequenced as part of The Cancer Genome Atlas (TCGA Website), a national effort to map the genomes of the many types of cancer. In this effort, researchers discovered that GBM has four distinct genetic subtypes that respond differently to aggressive therapies, making treatment extremely difficult and challenging. Parallel research Parallel research at Johns Hopkins University also contributed to the expansion of genomic information on GBM.

Characteristics:

Can be composed of several different cell types
Can develop directly or evolve from lower grade astrocytoma or oligodendroglioma
Most common in older individuals and more common in men than women
Less common in children
Median survival rate of ~15 months; 5-year survival rate of ~4%
The cause is unknown, but increasingly research is pointing toward genetic mutations

[kabunushi]

Just maybe because the trial is for glioblastoma which is far, far worse than the many other types of brain cancers included in the 5 year statistic which you quoted. Just to give you what wiki says on this:

...Despite maximum treatment, the cancer usually recurs.[3] The most common length of survival following diagnosis is 12 to 15 months with less than 3% to 5% of people surviving longer than five years.[2][3] Without treatment survival is typically 3 months.[9] I

Thanks for playing guy, better luck next time - but you might want to try getting a clue before posting 'information' that you think is news to longs.